Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin
NCT ID: NCT00597025
Last Updated: 2020-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
375 participants
INTERVENTIONAL
2007-12-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Protein Supplementation in Dialysis Patients
NCT01855295
Protein Supplementation in Dialysis Patients
NCT00367198
Nutritional Interventions in Peritoneal Dialysis Patients with Hypoalbuminemia
NCT04546958
Protein, Nutrition and Cardiovascular Disease in Stage 5 Chronic Kidney Disease
NCT00566670
Effects of Low Protein Diet in Preventing the Progression of Chronic Kidney Disease(CKD)---a Prospective Study
NCT02886975
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Center Hemodialysis patients
Protein Food Bar Intelligent Indulgence
Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
Group B
Center hemodialysis patients
Protein Food Bar Intelligent Indulgence
Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
Group C
Center Hemodialysis Patients
No interventions assigned to this group
Group D
Peritoneal dialysis patients
Protein Food Bar Intelligent Indulgence
Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
Group E
Peritoneal dialysis patients
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Protein Food Bar Intelligent Indulgence
Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
Protein Food Bar Intelligent Indulgence
Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
Protein Food Bar Intelligent Indulgence
Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age or older.
* Must have a reasonable expectation of remaining on treatment for at least 3 months.
* Must have an average serum albumin of \<3.5 g/dL over the three months prior to entry into the study.
* Must be able to understand and sign the informed consent.
* Must be willing and able to participate in nutrition interviews for determination of nutrient intake from conventional foods.
Exclusion Criteria
* Documented ongoing acute infection or inflammatory process including treatment with antibiotics within a two week time of study entry.
* Severe acidosis defined as pre-dialysis serum bicarbonate levels of \<15 mEq/L.
* Presence of conditions that would affect normal response to repletion of protein and calories, such as gastrointestinal disorders including inflammatory bowel disease.
* Hospitalization for an infectious condition within 4 weeks prior to study entry.
* Planned surgery within the three month study period including planned kidney transplantation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Satellite Healthcare
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brigitte Schiller-Moran, MD
Role: PRINCIPAL_INVESTIGATOR
Satellite Healthcare, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Satellite Healthcare, Inc.
Mountain View, California, United States
WellBound, Inc.
Mountain View, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SR017PB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.